首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2440056篇
  免费   188454篇
  国内免费   7956篇
耳鼻咽喉   33404篇
儿科学   80246篇
妇产科学   68454篇
基础医学   344621篇
口腔科学   69498篇
临床医学   213099篇
内科学   491503篇
皮肤病学   56592篇
神经病学   196458篇
特种医学   96384篇
外国民族医学   618篇
外科学   376106篇
综合类   52995篇
现状与发展   3篇
一般理论   711篇
预防医学   192227篇
眼科学   54615篇
药学   178127篇
  6篇
中国医学   4676篇
肿瘤学   126123篇
  2018年   26577篇
  2016年   22765篇
  2015年   25675篇
  2014年   35205篇
  2013年   53321篇
  2012年   70427篇
  2011年   75490篇
  2010年   45377篇
  2009年   42656篇
  2008年   70522篇
  2007年   75840篇
  2006年   76801篇
  2005年   74886篇
  2004年   71356篇
  2003年   69238篇
  2002年   66801篇
  2001年   110391篇
  2000年   113981篇
  1999年   95761篇
  1998年   28169篇
  1997年   25217篇
  1996年   26039篇
  1995年   25483篇
  1994年   24014篇
  1993年   22360篇
  1992年   78235篇
  1991年   76509篇
  1990年   74470篇
  1989年   71317篇
  1988年   66454篇
  1987年   65152篇
  1986年   62012篇
  1985年   59424篇
  1984年   44983篇
  1983年   38427篇
  1982年   23670篇
  1981年   21149篇
  1980年   19843篇
  1979年   41700篇
  1978年   29821篇
  1977年   25435篇
  1976年   23700篇
  1975年   25530篇
  1974年   30056篇
  1973年   28874篇
  1972年   27043篇
  1971年   25085篇
  1970年   23133篇
  1969年   22082篇
  1968年   20745篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.

Objective

Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.

Methods

Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.

Results

In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.

Conclusions

Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection.  相似文献   
42.
Metabolism describes the series of chemical reactions that are concerned with the provision of energy to biological systems. They may be divided into reactions involved in energy yield (catabolism: demand exceeds supply), and energy storage (anabolism: supply exceeds demand). Regulation of these pathways is critical for homeostasis, and derangements in metabolism are seen in a wide variety of pathological processes. Understanding metabolism is key to the treatment of many diseases, notably diabetes, as well as underpinning clinical nutritional support.  相似文献   
43.
Chondrocytes are the main cells in the extracellular matrix (ECM) of articular cartilage and possess a highly differentiated phenotype that is the hallmark of the unique physiological functions of this specialised load-bearing connective tissue. The plasma membrane of articular chondrocytes contains a rich and diverse complement of membrane proteins, known as the membranome, which defines the cell surface phenotype of the cells. The membranome is a key target of pharmacological agents and is important for chondrocyte function. It includes channels, transporters, enzymes, receptors, and anchors for intracellular, cytoskeletal and ECM proteins and other macromolecular complexes. The chondrocyte channelome is a sub-compartment of the membranome and includes a complete set of ion channels and porins expressed in these cells. Many of these are multi-functional proteins with “moonlighting” roles, serving as channels, receptors and signalling components of larger molecular assemblies. The aim of this review is to summarise our current knowledge of the fundamental aspects of the chondrocyte channelome, discuss its relevance to cartilage biology and highlight its possible role in the pathogenesis of osteoarthritis (OA). Excessive and inappropriate mechanical loads, an inflammatory micro-environment, alternative splicing of channel components or accumulation of basic calcium phosphate crystals can result in an altered chondrocyte channelome impairing its function. Alterations in Ca2+ signalling may lead to defective synthesis of ECM macromolecules and aggravated catabolic responses in chondrocytes, which is an important and relatively unexplored aspect of the complex and poorly understood mechanism of OA development.  相似文献   
44.
45.
46.
47.
48.
Henna, derived from a combination of natural leaves and coloring additives, is a common decorative dye traditionally used in many Islamic religious celebrations. Para‐phenylenediamine (PPD), a major component of black henna tattoo, is a strong sensitizer and common allergen. We report a case of severe connubial allergic contact dermatitis after black henna heterotransfer in a girl.  相似文献   
49.
50.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号